• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
78,344.62 580.71
( 0.75%)
Global Indices
Nasdaq
52,921.07 594.83
(1.14%)
Dow Jones
7,504.24 0.01
(0.00%)
Hang Seng
69,576.15 -167.92
(-0.24%)
Nikkei 225
10,673.34 20.47
(0.19%)
Forex
USD-INR
95.28 0.28
(0.30%)
EUR-INR
108.75 0.54
(0.50%)
GBP-INR
126.99 1.06
(0.84%)
JPY-INR
0.59 0.01
(0.97%)

EQUITY - MARKET SCREENER

Fredun Pharmaceuticals Ltd
Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value()
539730
INE194R01017
489.430006
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
42.97
1427.13
EPS(TTM)
Face Value()
Div & Yield %
60.24
10
0.03
 

Balkrishna Inds drops after Q4 PAT slumps 18% YoY to Rs 295 cr
May 11,2026
Profit before tax (PBT) fell 16.91% YoY to Rs 394.99 crore in Q4 March 2026.

Sales volume rose 5% to 85,820 MT in Q4 FY26 compared with 82,062 MT in Q4 FY25.

EBITDA stood at Rs 663 crore in Q4 FY26, registering de-growth of 6% compared with Rs 703 crore uin Q4 FY25. EBITDA margin contracted to 22.9% in Q4 FY26 as against 24.8% in Q4 FY25.

Meanwhile, the company’s board recommended payment of final dividend of Rs 4 per equity share with a face value of Rs 2 each for year ended 31st March 2026.

Balkrishna Industries is engaged in the business of manufacturing and selling of 'off-highway tyres' (OHT) in the specialist segments such as agricultural, industrial & construction, earthmovers & port, mining, forestry, lawn & garden and all terrain vehicles (ATV).